Document is current
Any future updates will be listed below
-
Authors
Holesova, Zuzana
Pös, Ondrej
Gazdarica, Juraj
Kucharik, Marcel
Budis, Jaroslav
Hyblova, Michaela
Minarik, Gabriel
Szemes, Tomas
-
Funding
Funding for this research was provided by:
Horizon 2020 (872539 (PANGAIA), 872539 (PANGAIA), 872539 (PANGAIA), 956229 (ALPACA))
Agentúra na Podporu Výskumu a Vývoja (APVV-21-0296 (INCAM), APVV-21-0296 (INCAM), APVV-21-0296 (INCAM))
European Regional Development Fund,European Union (ITMS: 313021BUZ3 (USCCCORD), ITMS: 313021BUZ3 (USCCCORD), ITMS: 313021BUZ3 (USCCCORD), ITMS: 313021BUZ3 (USCCCORD))
European Regional Development Fund (ITMS: 313011AVH7 (DiaCovid), ITMS: 313011AVH7 (DiaCovid))
- License Information
-
More Information
Article History
Received: 28 December 2023
Accepted: 28 March 2024
First Online: 15 April 2024
Declarations
:
: All the enrolled participants gave written informed consent for inclusion in this study. The study was conducted following the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Bratislava Self-Governing Region on 30 June 2015 (03899/2015/HF), 25 March 2020 (05006/2020/HF/2) and 17 January 2023 (4530/2023/HF).
: Not Applicable.
: We declare a potential competing financial interest in the form of employee contracts (see affiliations for each author) with Geneton Ltd. and TrisomyTest Ltd. Geneton Ltd. participated in the development of a commercial NIPT test in Slovakia; however, it is not a provider of this commercial test, but continues to do basic and applied research in the field of NIPT. On the other hand, TrisomyTest Ltd. is the commercial provider of NIPT testing in Slovakia. Its participation in the study was limited to the routine NIPT testing that generated the genomic results reused in our research. Related to this work, there are no patents, products in development, or marketed products to declare. The authors declare no other conflict of interest.
